Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Hypertension
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Hypertension
    Amlodipine Plus Valsartan Reduces Blood Pressure Reductions Better Than Monotherapy in Black Patients With Severe Hypertension: Presented at ASH(HYP) - (DGDispatch)
    TopAbstracts in Hypertension 05/14/2008 - (DGNews)
    TopAbstracts in Hypertension 05/07/2008 - (DGNews)
    Kidney Disease Substantially Worsens in One-Fourth of African Americans Despite Hypertension Treatment - (DGNews)
    TopAbstracts in Hypertension 04/30/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Hypertension
    • Improving Outcomes in Hypertension and Congestive Heart Failure: Focus on New Generation ß-Blockers
    • Tackling a Silent Threat: Implications and Management of Peripheral Artery Disease
    • Peripheral Artery Disease: A Highly Prevalent Disease Remains Underdiagnosed and Undertreated
    • Pharmacotherapeutic Treatments for Hypertension Complicated with Proteinuria
      Hypertension in the Elderly

      Webcasts/CME archive

       Recent cases - Hypertension
        Dilation of Renal Artery Stenosis after Administration of Losartan
        Angioedema of the Tongue
        Primary Aldosteronism Caused by a Unilateral Adrenal Adenoma Accompanied by Autonomous Cortisol Secretion
        A Case of Hyperreninemic Hypertension with Bilateral Positive Captopril Renography but without Renovascular Stenosis
        Unusual Sequel of Successful Laparoscopic Unilateral Adrenalectomy in a Hypertensive Adolescent

        Cases archive
          




        my personal edition > hypertension > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Rosiglitazone May Improve Small Artery Elasticity in Patients With Diabetes

        A DGReview of :"Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus"
        American Journal of Hypertension

        08/19/2003
        By Emma Hitt, PhD


        Treatment with rosiglitazone may decrease hyperinsulinemia and, as a result, improve small artery elasticity, according to the findings of an open-label study.

        Hyperinsulinemia and insulin resistance (IR) play a major role in the pathogenesis of non-insulin dependent diabetes mellitus (NIDDM) and tissue damage, the authors note. In addition, diabetic patients have high rates of hypertension, dyslipidaemia, obesity, and an increased prevalence of vascular complications.

        Marina Shargorodsky, MD, with Departments of Department of Endocrinology and Diabetes at the Wolfson Medical Center, Holon, Israel, and colleagues hypothesised that glitazones may improve IR and reduce hyperinsulinemia and therefore reduce these complications.

        To test their theory, they recruited 52 patients with NIDDM and at least one additional cardiovascular risk factor. Patients were treated for 6 months with 4 mg per day of rosiglitazone. The dose was increased to 8 mg after 3 months of treatment if needed.

        Blood insulin and C-peptide levels and urine protein levels were measured at the beginning and end of the study. Glucose, chemistry, lipid profile, and haemoglobin A1C were measured at 0, 3, and 6 months, and vascular compliance was measured each month.

        Rosiglitazone increased small artery elasticity significantly, with a mean increase of up to 50% during monthly follow-up in comparison to baseline measurements (p<0.001). Large artery elasticity tended to increase toward the end of the study, but the change was not significant.

        Systolic blood pressure decreased from 144 to 124 mmHg, and diastolic blood pressure decreased from 80 to 68 mmHg, despite the patients' weight gain (p= 0.00008). Decrease in heart rate was not significant.

        Systemic vascular resistance decreased from 1789.8 to 1329.4 dyne sec/cm5 (p=0.0001). In patients not treated with insulin, plasma insulin decreased from 42.45 ± 24.90 to 27.86 ± 14.86 IU/mL (p=0.0001).

        "Because rosiglitazone improves insulin receptor sensitivity (IRS), it is logical to assume that the reduction in hyperinsulinemia reflects improvement in IRS," they conclude.

        "These findings comply with the theory that hyperinsulinemia and insulin resistance participate in the development of tissue damage, a progressive decrease in small artery elasticity," they add.
        Am J Hypertens 2003;16:8:617-22. "Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send